Tags

Type your tag names separated by a space and hit enter

Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients.
Acta Trop. 2004 Oct; 92(2):127-32.AT

Abstract

Pentavalent antimonial drugs are habitually the first choice for treating leishmaniasis, although they possess well-known toxicity and may present some therapeutic failure. Lipid formulations of amphotericin B (LFAB) have been increasingly used for treating several types of leishmaniasis. However, the administration of such lipid formulations specifically to patients with cutaneous leishmaniasis (CL) is still rare, including immunocompromised patients to whom standard treatments are more frequently contraindicated. We describe here two cases of immunocompromised patients with CL, one of them with AIDS, representing the first case of AIDS and CL co-infection treated with LFAB described in the literature. The patient achieved therapeutic success with a total 1.500 mg dose of amphotericin B colloidal dispersion. The other had diabetes mellitus as well as kidney failure and was under dialysis, having obtained the healing of lesion with a total dose of 600 mg of liposomal amphotericin B. Thus, the authors suggest that LFAB can represent a safe, efficient and less toxic therapeutic alternative to pentavalent antimonials, as well as to the so-called second line drugs, pentamidine and amphotericin B deoxycholate.

Authors+Show Affiliations

Amato VS
Infectious and Parasitic Diseases Clinic, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Avenida Dr. Enéas de Carvalho Aguiar 255, São Paulo, Brazil. valdirsa@netpoint.com.br
Rabello A
No affiliation info available
Rotondo-Silva A
No affiliation info available
Kono A
No affiliation info available
Maldonado TP
No affiliation info available
Alves IC
No affiliation info available
Floeter-Winter LM
No affiliation info available
Neto VA
No affiliation info available
Shikanai-Yasuda MA
No affiliation info available

MeSH

Acquired Immunodeficiency SyndromeAdultAmphotericin BAntiprotozoal AgentsDrug CombinationsHumansImmunocompromised HostKidney Failure, ChronicLeishmaniasis, CutaneousLiposomesMaleMiddle AgedPhosphatidylcholinesPhosphatidylglycerols

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

15350864

Citation

Amato, Valdir S., et al. "Successful Treatment of Cutaneous Leishmaniasis With Lipid Formulations of Amphotericin B in Two Immunocompromised Patients." Acta Tropica, vol. 92, no. 2, 2004, pp. 127-32.
Amato VS, Rabello A, Rotondo-Silva A, et al. Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients. Acta Trop. 2004;92(2):127-32.
Amato, V. S., Rabello, A., Rotondo-Silva, A., Kono, A., Maldonado, T. P., Alves, I. C., Floeter-Winter, L. M., Neto, V. A., & Shikanai-Yasuda, M. A. (2004). Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients. Acta Tropica, 92(2), 127-32.
Amato VS, et al. Successful Treatment of Cutaneous Leishmaniasis With Lipid Formulations of Amphotericin B in Two Immunocompromised Patients. Acta Trop. 2004;92(2):127-32. PubMed PMID: 15350864.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients. AU - Amato,Valdir S, AU - Rabello,Ana, AU - Rotondo-Silva,Alexandre, AU - Kono,Adriana, AU - Maldonado,Tânia Patrícia H, AU - Alves,Isabel C, AU - Floeter-Winter,Lucile M, AU - Neto,Vicente Amato, AU - Shikanai-Yasuda,Maria Aparecida, PY - 2004/04/04/received PY - 2004/06/22/revised PY - 2004/06/24/accepted PY - 2004/9/8/pubmed PY - 2004/10/27/medline PY - 2004/9/8/entrez SP - 127 EP - 32 JF - Acta tropica JO - Acta Trop VL - 92 IS - 2 N2 - Pentavalent antimonial drugs are habitually the first choice for treating leishmaniasis, although they possess well-known toxicity and may present some therapeutic failure. Lipid formulations of amphotericin B (LFAB) have been increasingly used for treating several types of leishmaniasis. However, the administration of such lipid formulations specifically to patients with cutaneous leishmaniasis (CL) is still rare, including immunocompromised patients to whom standard treatments are more frequently contraindicated. We describe here two cases of immunocompromised patients with CL, one of them with AIDS, representing the first case of AIDS and CL co-infection treated with LFAB described in the literature. The patient achieved therapeutic success with a total 1.500 mg dose of amphotericin B colloidal dispersion. The other had diabetes mellitus as well as kidney failure and was under dialysis, having obtained the healing of lesion with a total dose of 600 mg of liposomal amphotericin B. Thus, the authors suggest that LFAB can represent a safe, efficient and less toxic therapeutic alternative to pentavalent antimonials, as well as to the so-called second line drugs, pentamidine and amphotericin B deoxycholate. SN - 0001-706X UR - https://www.unboundmedicine.com/medline/citation/15350864/Successful_treatment_of_cutaneous_leishmaniasis_with_lipid_formulations_of_amphotericin_B_in_two_immunocompromised_patients_ DB - PRIME DP - Unbound Medicine ER -